In reference to “Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer”

Journal Article In reference to "Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer" Get access Pietro De Luca , Pietro De Luca Laboratory of Neuromotor Physiology, IRCCS Foundation Santa Lucia, Rome, ItalyOtolaryngology Department, Santa Rosa Hospital, Viterbo, Italy Corresponding author. Laboratory of Neuromotor Physiology, IRCCS Foundation Santa Lucia, Rome, Italy. E-mail: [email protected] https://orcid.org/0000-0002-6505-1680 Search for other works by this author on: Oxford Academic PubMed Google Scholar Luca de Campora , Luca de Campora Otolaryngology Department, Santa Rosa Hospital, Viterbo, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Claudio Viti , Claudio Viti Otolaryngology Department, Santa Rosa Hospital, Viterbo, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Angelo Camaioni Angelo Camaioni Head and Neck Department, Nostra Signora della Mercede Clinic, Rome, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Japanese Journal of Clinical Oncology, hyaf137, https://doi.org/10.1093/jjco/hyaf137 Published: 29 August 2025 Article history Received: 21 July 2025 Editorial decision: 08 August 2025 Accepted: 16 August 2025 Published: 29 August 2025